Inhibition of glypican-3 expression via RNA interference influences the growth and invasive ability of the MHCC97-H human hepatocellular carcinoma cell line

International Journal of Molecular Medicine

Volumn 28, Issue 4, 2011, Pages 497-503

  Ruan, Jian ^a   Liu, Feiye ^a   Chen, Xiaohua ^b   Zhao, Peng ^c   Su, Ning ^a   Xie, Guozhu ^a   Chen, Jianpeng ^a   Zheng, Dayong ^a   Luo, Rongcheng ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b Panyu Central Hospital   (China)

^c ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Glypican 3; Hepatocellular carcinoma; Malignant behavior; RNA interference

Indexed keywords

GLYPICAN 3; SHORT HAIRPIN RNA;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL INVASION; CELL PROLIFERATION; DOWN REGULATION; GENE SILENCING; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; TUMOR XENOGRAFT;

ANIMALS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; GLYPICANS; HUMANS; LIVER NEOPLASMS; MICE; MICE, NUDE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79960761589     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2011.704     Document Type: Article

References (37)

1. Tung-Ping PR, Fan ST and Wong J: Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg 232: 10-24, 2000.
2. Capocaccia R, Sant M, Berrino F, Simonetti A, Santi V and Trevisani F: Hepatocellular carcinoma: trends of incidence and survival in Europe and the United States at the end of the 20th century. Am J Gastroenterol 102: 1660-1671, 2007.
3. Ng KK, Lo CM, Liu CL, Poon RT, Chan SC and Fan ST: Survival analysis of patients with transplantable recurrent hepato-cellular carcinoma: implications for salvage liver transplant. Arch Surg 143: 68-74, 2008. (Pubitemid 351159293)
4. Li M, Choo B, Wong ZM, Filmus J and Buick RN: Expression of OCI-5/glypican 3 during intestinal morphogenesis: regulation by cell shape in intestinal epithelial cells. Exp Cell Res 235: 3-12, 1997. (Pubitemid 27381675)
5. Pellegrini M, Pilia G, Pantano S, et al: Gpc3 expression correlates with the phenotype of the Simpson-Golabi-Behmel syndrome. Dev Dyn 213: 431-439, 1998. (Pubitemid 28546122)
6. Pilia G, Hughes-Benzie RM, MacKenzie A, et al: Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome. Nat Genet 12: 241-247, 1996. (Pubitemid 26080081)
7. Cano-Gauci DF, Song HH, Yang H, et al: Glypican-3-deficient mice exhibit developmental overgrowth and some of the abnormalities typical of Simpson-Golabi-Behmel syndrome. J Cell Biol 146: 255-264, 1999. (Pubitemid 29349979)
8. Gonzalez AD, Kaya M, Shi W, Song H, Testa JR, Penn LZ and Filmus J: OCI-5/GPC3, a glypican encoded by a gene that is mutated in the Simpson-Golabi-Behmel overgrowth syndrome, induces apoptosis in a cell line-specific manner. J Cell Biol 141: 1407-1414, 1998. (Pubitemid 28289915)
9. Peters MG, Farias E, Colombo L, Filmus J, Puricelli L and Bal Bal de Kier Joffé E: Inhibition of invasion and metastasis by glypican-3 in a syngeneic breast cancer model. Breast Cancer Res Treat 80: 221-232, 2003.
10. Capurro MI, Xiang YY, Lobe C and Filmus J: Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Res 65: 6245-6254, 2005. (Pubitemid 40994410)
11. Sakurai M, Shibata K, Umezu T, et al: Growth-suppressing function of glypican-3 (GPC3) via insulin like growth factor II (IGF-II) signaling pathway in ovarian clear cell carcinoma cells. Gynecol Oncol 119: 332-336, 2010.
12. Sung YK, Hwang SY, Park MK, et al: Glypican-3 is overexpressed in human hepatocellular carcinoma. Cancer Sci 94: 259-262, 2003. (Pubitemid 36575892)
13. Tuschl T: Expanding small RNA interference. Nat Biotechnol 20: 446-448, 2002.
14. Gomaa AI, Khan SA, Toledano MB, Waked I and Taylor-Robinson SD: Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol 14: 4300-4308, 2008.
15. Llovet JM, Ricci S, Mazzaferro V, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390, 2008.
16. Zhu AX, Sahani DV, Duda DG, et al: Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol 27: 3027-3035, 2009.
17. Bekaii-Saab T, Markowitz J, Prescott N, et al: A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res 15: 5895-5901, 2009.
18. Zhu ZW, Friess H, Wang L, et al: Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. Gut 48: 558-564, 2001. (Pubitemid 32234802)
19. Yasuda E, Kumada T, Toyoda H, et al: Evaluation for clinical utility of GPC3, measured by a commercially available ELISA kit with Glypican-3 (GPC3) antibody, as a serological and histological marker for hepatocellular carcinoma. Hepatol Res 40: 477-485, 2010.
20. Hsu HC, Cheng W and Lai PL: Cloning and expression of a developmentally regulated transcript MXR7 in hepatocellular carcinoma: biological significance and temporospatial distribution. Cancer Res 57: 5179-5184, 1997. (Pubitemid 27498138)
21. Shirakawa H, Suzuki H, Shimomura M, et al: Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma. Cancer Sci 100: 1403-1407, 2009.
22. Tian J, Tang ZY, Ye SL, Liu YK, Lin ZY, Chen J and Xue Q: New human hepatocellular carcinoma (HCC) cell line with highly metastatic potential (MHCC97) and its expressions of the factors associated with metastasis. Br J Cancer 81: 814-821, 1999. (Pubitemid 29504690)
23. Li Y, Tang ZY, Ye SL, et al: Establishment of cell clones with different metastatic potential from the metastatic hepatocellular carcinoma cell line MHCC97. World J Gastroenterol 7: 630-636, 2001. (Pubitemid 32994410)
24. Cheng W, Tseng CJ, Lin TT, Cheng I, Pan HW, Hsu HC and Lee YM: Glypican-3-mediated oncogenesis involves the Insulin-like growth factor-signaling pathway. Carcinogenesis 29: 1319-1326, 2008.
25. Filmus J and Capurro M: The role of glypican-3 in the regulation of body size and cancer. Cell Cycle 7: 2787-2790, 2008.
26. Liu B, Bell AW, Paranjpe S, et al: Suppression of liver regeneration and hepatocyte proliferation in hepatocyte-targeted glypican 3 transgenic mice. Hepatology 52: 1060-1067, 2010.
27. Farooq M, Hwang SY, Park MK, Kim JC, Kim MK and Sung YK: Blocking endogenous glypican-3 expression releases Hep 3B cells from G1 arrest. Mol Cells 15: 356-360, 2003.
28. Sung YK, Hwang SY, Farooq M, Kim JC and Kim MK: Growth promotion of HepG2 hepatoma cells by antisense-mediated knockdown of glypican-3 is independent of insulin-like growth factor 2 signaling. Exp Mol Med 35: 257-262, 2003. (Pubitemid 37152638)
29. Lin H, Huber R, Schlessinger D and Morin PJ: Frequent silencing of the GPC3 gene in ovarian cancer cell lines. Cancer Res 59: 807-810, 1999. (Pubitemid 29086731)
30. Murthy SS, Shen T, De Rienzo A, et al: Expression of GPC3, an X-linked recessive overgrowth gene, is silenced in malignant mesothelioma. Oncogene 19: 410-416, 2000. (Pubitemid 30077342)
31. Xiang YY, Ladeda V and Filmus J: Glypican-3 expression is silenced in human breast cancer. Oncogene 20: 7408-7412, 2001. (Pubitemid 33078211)
32. Zhu Z, Friess H, Kleeff J, et al: Glypican-3 expression is markedly decreased in human gastric cancer, but not in esophageal cancer. Am J Surg 184: 78-83, 2002. (Pubitemid 34804883)
33. Powell CA, Xu G, Filmus J, Busch S, Brody JS and Rothman PB: Oligonucleotide microarray analysis of lung adenocarcinoma in smokers and nonsmokers identifies GPC3 as a potential lung tumor suppressor. Chest 121 (3 Suppl): S6-S7, 2002.
34. Kim H, Xu GL, Borczuk AC, et al: The heparan sulfate proteo-glycan GPC3 is a potential lung tumor suppressor. Am J Respir Cell Mol Biol 29: 694-701, 2003. (Pubitemid 38054366)
35. Buchanan C, Stigliano I, Garay-Malpartida HM, et al: Glypican-3 reexpression regulates apoptosis in murine adenocarcinoma mammary cells modulating PI3K/Akt and p38MAPK signaling pathways. Breast Cancer Res Treat 119: 559-574, 2010.
36. Lai JP, Sandhu DS, Yu C, et al: Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma. Hepatology 47: 1211-1222, 2008. (Pubitemid 351547907)
37. Midorikawa Y, Ishikawa S, Iwanari H, et al: Glypican-3, over-expressed in hepatocellular carcinoma, modulates FGF2 and BMP-7 signaling. Int J Cancer 103: 455-465, 2003. (Pubitemid 36020219)